The INCATE Selection Committee has selected five promising ventures to receive Stage I support.

Want to find out who they are? Explore the latest additions and learn more about the innovative ideas moving forward in the INCATE program.

Inicure AB – I-CURE: Small molecule FPR1 agonists treat and cure resistant bacterial infections by boosting the natural Innate Immune system without the risk of antibiotic resistance.

Obulytix – Engineered biologics for rapid, precise elimination of MDR Gram-negative infections.

The Wright Lab – The Wright lab is pursuing two first—in-class antibiotic semi-synthetic peptides, a lasso peptide with broad-spectrum bactericidal activity and a Type V glycopeptide with potent activity against drug-resistant gram-positive pathogens.

University Hospital Cologne – This project advances highly potent, fully human monoclonal antibodies targeting the Type III secretion system of Pseudomonas aeruginosa for difficult-to-treat infections.

Veirulence – We will conduct a proof-of-concept study demonstrating that our first-in-class mechanism mediates pathogenic behaviour in P. aeruginosa and enhances antibiotic activity.

Learn more about all the Stage I ventures selected in previous sessions HERE.